|10 July, 2016

Boehringer Ingelheim opens its new office in Kuwait

Boehringer Ingelheim opened its new office in Kuwait.

Boehringer Ingelheim opens its new office in Kuwait
10 July 2016
The company plans to increase its presence in Kuwait to reach a team of 25-30 employees
Kuwait City - 10th July, 2016

Boehringer Ingelheim, one of the world's leading pharmaceutical companies, announced today that it has recently opened its new office in the State of Kuwait. The opening ceremony was held in YIACO Medical Company's (YIACO) headquarters, in Salmiya, and where senior representatives from both companies were present.

YIACO's management team included Dr. Bader Altraiji, Chief Executive Officer; Dr. Mohamed Barham, Chief Operational Officer; Dr. Fawaz Al Omi, Chief Communications Officer and Dr. Abdulla Al Bader, Pharmaceutical and Healthcare Manager. Representing Boehringer Ingelheim were Mazen Bachir, Country Manager - Gulf and Iran and the company's wider team in Kuwait.

During the opening ceremony, Mazen Bachir said, "Kuwait is an important market for Boehringer Ingelheim's operations in the region, and we are proud to collaborate with our agent, YIACO, to deliver patient focused solutions.  Our commitment to excellence and comprehensive understanding of patient needs in Kuwait makes us confident to deliver value across a number of therapeutic areas including diabetes, respiratory, cardiovascular diseases as well as lung cancer."

"Our aim is to continue growing our presence in Kuwait to reach a team of 25-30 employees while increasing our overall business in the coming few years," added Bachir.

Moreover, Dr. Bader Al Traji, Chief Executive Officer of YIACO also said, "The continued growth of Kuwait's population and rise in conditions such as diabetes and obesity has prompted more demands for a stronger healthcare offering. We are proud to partner with Boehringer Ingelheim to expand their presence across the country with an underlying objective of further enhancing community wellbeing."

Boehringer Ingelheim is committed to research into patient populations to improve the overall understanding of their conditions and patient experiences.

-Ends-

About Boehringer Ingelheim
Boehringer Ingelheim is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates globally through 145 affiliates and a total of some 47,500 employees. The focus of the family-owned company, founded in 1885, is on researching, developing, manufacturing and marketing new medications of high therapeutic value for human and veterinary medicine.

Social responsibility is an important element of the corporate culture at Boehringer Ingelheim. This includes worldwide involvement in social projects through, for example, the initiative "Making More Health" while also caring for employees. Respect, equal opportunity and reconciling career and family form the foundation of mutual cooperation. The company also focuses on environmental protection and sustainability in everything it does.

In 2015, Boehringer Ingelheim achieved net sales of about 14.8 billion euros. R&D expenditure corresponds to 20.3 per cent of net sales.

For more information please visit www.boehringer-ingelheim.com

About YIACO
Founded in 1953, YIACO Medical Company, Kuwait's leading marketing agent for multinational research-based pharmaceuticals manufacturers as well as medical and dental equipment, was established to cater to the modern healthcare system in Kuwait and abroad. A leading healthcare network, YIACO Medical Company has successfully diversified in heath sector with business divisions in pharmaceuticals, medical and dental equipment, as well as medical centers and a pharmacy chain. Listed in the Kuwait Stock Exchange since 2007, the organization has a proven track record in delivering intelligent and innovative solutions that keep patient and community wellbeing the center of its focus. For more information please visit www.yiacokuwait.com.

For more information, please contact:
Emeel Bishay
Account Director | Healthcare
FleishmanHillard
T: + 971 4450 2600
Emeel.Bishay@fleishman.com

Sara Shamel
Communications Manager - NEMEA
Boehringer Ingelheim
T: +971 553258101
sara.shamel@boehringer-ingelheim.com

© Press Release 2016

More From Press Releases